

**Amendments to the Claims:**

The following listing of claims replaces all prior versions and listings of claims in the application:

1-30 (canceled)

31. (Presently amended) A glycoconjugate produced by the a method of claim 20 comprising:

(a) providing a heterogenous population of *Neisseria meningitidis* serogroup B capsular oligosaccharide (MenB OS) derivatives in which sialic acid residue N-acetyl groups are replaced with N-acyl groups;

(b) obtaining a substantially homogenous group of MenB OS derivatives from the population of (a) wherein said group of MenB OS derivatives has an average Dp of about 10 to 20;

(c) introducing a reactive group at a reducing end of the derivatives obtained in step (b) to provide single end-activated MenB OS derivatives; and

(d) covalently attaching the end-activated MenB OS derivatives to a carrier molecule to provide a MenB OS glycoconjugate comprising substantially homogenous sized MenB OS moieties.

32. (Presently amended) A glycoconjugate produced by the a method of claim 27 comprising:

(a) providing a heterogenous population of *Neisseria meningitidis* serogroup B capsular oligosaccharide (MenB OS) derivatives in which sialic acid residue N-acetyl groups are replaced with N-propionyl groups;

(b) obtaining a substantially homogenous group of MenB OS derivatives from the population of (a) wherein said MenB OS derivatives have an average Dp of about 12 to 18;

(c) introducing a reactive group at a reducing end of the derivatives obtained in step (b) to provide single end-activated MenB OS derivatives; and

(d) covalently attaching the end-activated MenB OS derivatives to a CRM<sub>197</sub> bacterial toxoid carrier molecule to provide a MenB OS/CRM<sub>197</sub> toxoid glycoconjugate comprising substantially homogenous sized MenB OS moieties.

33-42. (Canceled)

43. (New) The glycoconjugate of claim 31, wherein the reactive group introduced in step (c) comprises an active ester group.

44. (New) The glycoconjugate of claim 31, wherein the sialic acid residue N-acetyl groups of the MenB OS derivatives are replaced with N-propionyl groups.

45. (New) The glycoconjugate of claim 44, wherein the carrier molecule is a bacterial toxoid.

46. (New) The glycoconjugate of claim 45, wherein the carrier molecule is a nontoxic mutant bacterial toxoid.

47. (New) The glycoconjugate of claim 31, wherein the MenB OS derivative has an average D<sub>p</sub> of about 12 to about 18.

48. (New) The glycoconjugatge of claim 31, wherein the MenB OS derivative further comprises a C<sub>3</sub>-C<sub>16</sub> long-chain aliphatic lipid covalently attached thereto.

49. (New) The glycoconjugate of claim 32, wherein the MenB OS derivative further comprises a C<sub>3</sub>-C<sub>16</sub> long-chain aliphatic lipid covalently attached thereto.